Center for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Palliat Support Care. 2013 Jun;11(3):223-9. doi: 10.1017/S1478951512001071. Epub 2013 Feb 11.
Although depression appears to be associated with worse survival from cancer, the underlying mechanisms of this association are unknown. Tumor epidermal growth factor receptor (EGFR) genotype is a known predictor of survival in metastatic non-small cell lung cancer (NSCLC) and appears to be associated with depression. We hypothesized that tumor EGFR genotype may account for a relationship between depression and survival in this population. We investigated this possible relationship in a cohort of patients with metastatic NSCLC, in which we had previously demonstrated an association between depression and worse survival.
A cohort of 151 patients with newly diagnosed metastatic NSCLC were enrolled and followed in a randomized controlled trial of early palliative care. At enrollment, 150 had depression assessed with the Patient Health Questionnaire-9 (PHQ-9), and categorical scoring for major depressive syndrome (MDS) was used for analyses. Patients with tumor tissue available underwent EGFR genotyping. Associations with survival were tested using Cox proportional hazards models, adjusting for potential confounders.
Twenty-one patients (14.0%) met criteria for MDS. Forty-four patients (29.3%) had EGFR genotyping, and 17 (38.6%) of these harbored EGFR mutations. Patients with EGFR mutations had significantly lower PHQ-9 scores (p = 0.03), and none met criteria for depression. EGFR mutations were significantly associated with superior survival (p = 0.02). When both depression and EGFR genotype were simultaneously entered into the model, only EGFR mutations remained significantly associated with survival (p = 0.02), and the effect of depression was attenuated.
Depression is associated with worse survival in metastatic NSCLC, and this relationship may be at least partially explained by tumor EGFR genotype. Further study into whether depression could be associated with specific biologic properties of cancer that vary by genotype is warranted.
尽管抑郁似乎与癌症患者的生存预后更差相关,但这种关联的潜在机制尚不清楚。肿瘤表皮生长因子受体(EGFR)基因型是转移性非小细胞肺癌(NSCLC)生存预后的已知预测因子,并且似乎与抑郁相关。我们假设肿瘤 EGFR 基因型可能解释了这一人群中抑郁与生存之间的关系。我们在一项转移性 NSCLC 患者队列研究中对此进行了研究,我们先前在该研究中证实了抑郁与生存预后更差之间存在关联。
招募了 151 例新诊断为转移性 NSCLC 的患者,并在一项早期姑息治疗的随机对照试验中对他们进行了随访。入组时,150 例患者使用患者健康问卷-9(PHQ-9)进行抑郁评估,并使用主要抑郁综合征(MDS)的分类评分进行分析。有肿瘤组织的患者进行 EGFR 基因分型。使用 Cox 比例风险模型对生存相关因素进行检验,调整了潜在混杂因素。
21 例患者(14.0%)符合 MDS 标准。44 例患者(29.3%)进行了 EGFR 基因分型,其中 17 例(38.6%)存在 EGFR 突变。EGFR 突变患者的 PHQ-9 评分显著较低(p = 0.03),且无一人符合抑郁标准。EGFR 突变与生存预后显著相关(p = 0.02)。当同时将抑郁和 EGFR 基因型纳入模型时,只有 EGFR 突变仍与生存预后显著相关(p = 0.02),而抑郁的影响减弱。
抑郁与转移性 NSCLC 患者的生存预后更差相关,这种关系至少部分可以由肿瘤 EGFR 基因型解释。进一步研究抑郁是否与因基因型而异的癌症特定生物学特性相关是有必要的。